Bexatamig
Multispecific antibody
Also known as SAR443579
Evidence outlook · program status
Discontinued (2025-08), as a strategic decision by the sponsor
All registered clinical studies (2/2) were terminated or withdrawn; NCT06508489 whyStopped: "Early discontinuation based on strategic sponsor decision not driven by any safety concerns". The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05086315 NCT05086315 · Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia This was an open-label, non-randomized, single-arm, first-in-human dose-escalation study of SAR443579 in relapsed or refractory acute leukemias and related blood cancers, with no control group. The primary goal was to find a safe dose by tracking dose-limiting toxicities, not to test efficacy, and the study was terminated before most of its planned expansion cohorts began. Registry: NCT05086315 | 1/2 | Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs) (Cycle 1 Day 1 up to Cycle 1 Day 28. Each cycle duration in induction period was 28 days.); Dose Escalation (Cohort C): Number of Participants With Dose Limiting Toxicities (Cycle 1 Day 1 to Cycle 1 Day 28. Each cycle duration in induction period was 28 days.); Dose Expansion (Cohorts A1, A2 and D): Composite Complete Remission (CRc) Rate (Tumors were assessed on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first. Maximum treatment duration was 20.9 weeks.); Dose Expansion (Cohort B): Overall Response Rate (ORR) (Tumors were planned to assess on Day 28 of each induction cycle and Day 56 of each maintenance cycle until disease relapse, unacceptable AE, discontinuation, or death, whichever occurred first.) 2025-06-13 | Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs) (Cycle 1 Day 1 up to Cycle 1 Day 28. Each cycle duration in induction period was 28 days.): Dose Escalation - Adult Arm: SAR443579 10-100 mcg/kg 0 Participants | Dose Escalation - Adult Arm: SAR443579 30-300 mcg/kg 0 Participants | Dose Escalation - Adult Arm: SAR443579 750 mcg/kg 1 Participants | Dose Escalation - Adult Arm: SAR443579 800 mcg/kg 0 Participants | Dose Escalation - Adult Arm: SAR443579 100-1000 mcg/kg 0 Participants | Dose Escalation - Adult Arm: SAR443579 300-1000 mcg/kg 0 Participants | Dose Escalation - Adult Arm: SAR443579 1000 mcg/kg 0 Participants | Dose Escalation - Adult Arm: SAR443579 1500 mcg/kg 0 Participants | Dose Escalation - Adult Arm: SAR443579 2000 mcg/kg 0 Participants | Dose Escalation - Adult Arm: SAR443579 1000-3000 mcg/kg 0 Participants | Dose Escalation - Adult Arm: SAR443579 3000 mcg/kg 0 Participants | Dose Escalation - Adult Arm: SAR443579 6000 mcg/kg 0 Participants | Dose Escalation - Pediatric Arm: SAR443579 1000 mcg/kg 0 Participants | Dose Escalation - Pediatric Arm: SAR443579 1500 mcg/kg 1 Participants | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
Other CD123 drugs
Pivekimab Sunirine, Tagraxofusp, CD123 targeted CAR-NK cells, Allo-RevCAR01-T, BYON4413. Compare all 6 CD123 drugs
5 other tracked programmes target this mechanism, 5 of them ahead of this one.
This drug's own stage for Acute Myeloid Leukemia: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Bexatamig: this drug | Discontinued | Multispecific antibody | CD123 | not yet graded | Featured results are dose-finding only in this race | |
| Azacitidine (Onureg) | Approved | Small molecule | DNMT1 (DNA methyltransferase 1) | Weak signal | NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results). | |
| Decitabine / Cedazuridine (Inqovi) | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | Partial signal | Featured results are non-efficacy only in this race | |
| Enasidenib (Idhifa) | Approved | Small molecule | IDH2 | Partial signal | NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed | |
| Gemtuzumab Ozogamicin | Approved | Antibody–drug conjugate | CD33 | Partial signal | NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients. | |
| Gilteritinib | Approved | Small molecule | FLT3 | Partial signal | NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed | |
| Glasdegib | Approved | Small molecule | Hedgehog Pathway Inhibitor | Partial signal | No reviewed efficacy summary in this indication | |
| Ivosidenib (Tibsovo) | Approved | Small molecule | Mutant IDH1 | Reliable signal | NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis) | |
| Midostaurin (Rydapt) | Approved | Small molecule | FLT3;KIT;PKC;PDGFR | Weak signal | NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results). | |
| Olutasidenib | Approved | Small molecule | Mutant IDH1 | Weak signal | Featured results are safety only in this race | |
| Orca-T (TREGZI) | Approved | Cell therapy | Allogeneic engineered T-cell immunotherapy | Partial signal | NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5) | |
| Quizartinib | Approved | Small molecule | FLT3 | Reliable signal | NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2) | |
| Revumenib | Approved | Small molecule | Menin | Weak signal | No reviewed efficacy summary in this indication | |
| Sargramostim (Leukine) | Approved | Protein / enzyme therapeutic | GM-CSF receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Tretinoin (Vesanoid) | ApprovedUS marketing discontinued | Small molecule | RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APL | not yet graded | NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending | |
| Venetoclax | Approved | Small molecule | BCL-2 | Reliable signal | NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed | |
| Vyxeos | Approved | Small molecule | DNA synthesis (cytarabine, antimetabolite) / Topoisomerase II | Partial signal | NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1). | |
| Ziftomenib | Approved | Small molecule | Menin | Weak signal | No reviewed efficacy summary in this indication | |
| 131I-Apamistamab | Phase 3 | Monoclonal antibody | CD45 | Partial signal | NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001 | |
| Arsenic Trioxide (QTX-2101) | Phase 3 | Small molecule | PML-RARA fusion oncoprotein | not yet graded | No reviewed efficacy summary in this indication | |
| Arsenic Trioxide (SDK001) | Phase 3 | Small molecule | PML-RARA fusion oncoprotein | Partial signal | No reviewed efficacy summary in this indication | |
| Azacitidine | Phase 3 | Small molecule | DNMT1 (DNA methyltransferase 1) | Partial signal | NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed | |
| Bleximenib | Phase 3 | Small molecule | Menin-KMT2A protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Clifutinib Besylate | Phase 3 | Small molecule | FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Crenolanib | Phase 3 | Small molecule | FLT3 (including D835/ITD mutants), also PDGFR-alpha/beta | Reliable signal | NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145) | |
| Galinpepimut-S | Phase 3 | Vaccine | WT1 (Wilms Tumor-1 protein) | Weak signal | NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47% | |
| Lisaftoclax | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mesutoclax | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mocravimod | Phase 3 | Small molecule | Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) | not yet graded | No reviewed efficacy summary in this indication | |
| Ruserontinib | Phase 3 | Small molecule | FLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes) | Partial signal | No reviewed efficacy summary in this indication | |
| XY0206 | Phase 3 | Small molecule | FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| Annamycin | Phase 2/3 | Small molecule | Topoisomerase II (TOP2) | not yet graded | No reviewed efficacy summary in this indication | |
| BL-M11D1 | Phase 2/3 | Antibody–drug conjugate | CD33 | not yet graded | No reviewed efficacy summary in this indication | |
| Pivekimab Sunirine (Decnupaz) | Phase 2/3 | Antibody–drug conjugate | CD123 | not yet graded | No reviewed efficacy summary in this indication | |
| Cusatuzumab | Phase 2 | Monoclonal antibody | CD70 | Weak signal | NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38 | |
| Lintuzumab-Ac225 | Phase 2 | Radiopharmaceutical | CD33 | Weak signal | No reviewed efficacy summary in this indication | |
| Pegargiminase | Phase 2 | Protein / enzyme therapeutic | Arginine-depleting pegylated arginine deiminase | Weak signal | NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months | |
| Prexigebersen | Phase 2 | RNA / oligonucleotide | GRB2 (growth factor receptor-bound protein 2) mRNA | Weak signal | Featured results are safety only in this race | |
| Romaciclib | Phase 2 | Small molecule | CDK8 / CDK19 | Weak signal | NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response | |
| Sonrotoclax (Beqalzi) | Phase 2 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tagraxofusp | Phase 2 | Protein / enzyme therapeutic | CD123 | Weak signal | No reviewed efficacy summary in this indication | |
| Vididencel | Phase 2 | Vaccine | Allogeneic dendritic cell vaccine | Weak signal | NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported). | |
| AB8939 | Phase 1/2 | Small molecule | Tubulin | not yet graded | No reviewed efficacy summary in this indication | |
| ABD-3001 | Phase 1/2 | Small molecule | ALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1) | not yet graded | No reviewed efficacy summary in this indication | |
| Alrizomadlin | Phase 1/2 | Small molecule | MDM2 | Weak signal | No reviewed efficacy summary in this indication | |
| ARD103 | Phase 1/2 | Cell therapy | CLL-1 (CLEC12A) | not yet graded | No reviewed efficacy summary in this indication | |
| AZD3632 | Phase 1/2 | Small molecule | Menin-KMT2A protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Bexmarilimab | Phase 1/2 | Monoclonal antibody | Clever-1 | not yet graded | No reviewed efficacy summary in this indication | |
| BG1805 | Phase 1/2 | Cell therapy | CLL-1 (CLEC12A) | not yet graded | No reviewed efficacy summary in this indication | |
| BSB-1001 | Phase 1/2 | Cell therapy | HA-1 (minor histocompatibility antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| CART84 | Phase 1/2 | Cell therapy | CD84 | not yet graded | No reviewed efficacy summary in this indication | |
| CCTx-001 | Phase 1/2 | Cell therapy | IL-1RAP | not yet graded | No reviewed efficacy summary in this indication | |
| CD123 Targeted CAR-NK Cells | Phase 1/2 | Cell therapy | CD123 | Weak signal | No reviewed efficacy summary in this indication | |
| CD123 / CD33 CART | Phase 1/2 | Cell therapy | CD123 / CD33 | not yet graded | No reviewed efficacy summary in this indication | |
| CLN-049 | Phase 1/2 | Multispecific antibody | FLT3, CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Debio 1562M | Phase 1/2 | Antibody–drug conjugate | CD37 | not yet graded | No reviewed efficacy summary in this indication | |
| Emavusertib | Phase 1/2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Enzomenib | Phase 1/2 | Small molecule | Menin-KMT2A protein-protein interaction | not yet graded | No reviewed efficacy summary in this indication | |
| Ligufalimab | Phase 1/2 | Monoclonal antibody | CD47 | not yet graded | No reviewed efficacy summary in this indication | |
| Mobinitinib | Phase 1/2 | Small molecule | FLT3 / Aurora kinase A and B | not yet graded | No reviewed efficacy summary in this indication | |
| MRX-2843 | Phase 1/2 | Small molecule | Flt3/MerTK | Weak signal | No reviewed efficacy summary in this indication | |
| Ocifisertib | Phase 1/2 | Small molecule | PLK4 (Polo-like kinase 4) | Weak signal | Featured results are safety only in this race | |
| Olverembatinib | Phase 1/2 | Small molecule | BCR-ABL (also AKT, c-Kit, ERK) | not yet graded | No reviewed efficacy summary in this indication | |
| OrcaGraft (Orca-Q) | Phase 1/2 | Cell therapy | Treg-enriched allogeneic haematopoietic stem cell graft | not yet graded | No reviewed efficacy summary in this indication | |
| Allo-RevCAR01-T | Phase 1 | Cell therapy | CD123 | not yet graded | No reviewed efficacy summary in this indication | |
| BYON4413 | Phase 1 | Antibody–drug conjugate | CD123 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 65 furthest-along competitors are listed; 65 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
No upcoming readouts on record for this asset.